glp-1 obesity drug news today october 23 2025 Novo Nordisk's weight-loss pill wins FDA approval Market Overview: GLP-1 Agonists and
Description
19 In regard to CKD, these clinical trials have also shown positive effects in the composite renal outcomes
doi: 10.1016/j.psc.2011.08.006
M., Andrade C
Perlis, L
Importantly, patients prefer, and are more likely to adhere to, an oral drug regimen versus an injectable alternative
Ensuring efficacy, safety, and durability comparable to injectable GLP-1 RAs while minimizing adverse effects, particularly gastrointestinal discomfort, is essential
